Asher Mullard

ottawa, ontario, canada

Publications:

Is this you?

Claim your profile to connect with sources, showcase your work, and earn extra income just by writing great stories.

About

I am a freelance science journalist, covering biological discoveries, drugs, clinical trials, and more. I have written for The Boston Globe, Nature, The Lancet, The New Scientist, The Walrus and many others.My work has been awarded honorary mention in the National Magazine Awards. I am a Contributing Editor for Nature Reviews Drug Discovery.

Featured Articles

2025 FDA approvals

Drug developers secured approvals for 46 new therapeutic agents from the FDA’s Center for Drug Evaluation and Research (CDER) in 2025. This cohort brings the 5-year average down a touch, to 48 new drugs per year (Fig. 1, Table 1). Approvals are still well... See more

nature.com•Asher Mullard•Jan 2, 2026

How common is Alzheimer's? Blood-test study holds surprises

Nearly one in ten people over the age of 70 have Alzheimer’s disease dementia, shows a first-of-its-kind study that paired blood-based markers and clinical assessments to study the disease in Norway1. That prevalence is in line with previous estimates for... See more

nature.com•Asher Mullard•Dec 17, 2025

FDA approves first gene therapy from a non-profit organization, but pricing and access questions remain

- NEWS IN BRIEF FDA approves first gene therapy from a non-profit organization, but pricing and access questions remain Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30... See more

nature.com•Asher Mullard•Dec 17, 2025

Betting on β-catenin inhibitors in oncology

- NEWS Betting on β-catenin inhibitors in oncology Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time Subscribe to this journal Receive 12 print issu... See more

nature.com•Asher Mullard•Dec 12, 2025

Novel antimalarial passes key phase III test

- NEWS IN BRIEF Novel antimalarial passes key phase III test Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time Subscribe to this journal Receive 12 ... See more

nature.com•Asher Mullard•Nov 26, 2025

Bylined Articles

HARO Queries

Portfolio

Is this you?

Claim your profile to connect with sources, showcase your work, and earn extra income just by writing great stories.

Claim your profile

Social Media

LinkedIn X

Social Media

Pitching Guidelines

Keep it short (under 200 words)
Include credentials and links
Use subject lines with query title

Pitching Guidelines

Quick Stats

Followers

958

Articles11

Last Article12 days ago

Stats

Education

Bachelor Of Science, Biochemistry at Queen'S UniversityGraduated: 2003

Education

Asher Mullard

Is this you?

About

Featured Articles

2025 FDA approvals

How common is Alzheimer's? Blood-test study holds surprises

FDA approves first gene therapy from a non-profit organization, but pricing and access questions remain

Betting on β-catenin inhibitors in oncology

Novel antimalarial passes key phase III test

Is this you?

Social Media

Education

Connect with journalists.

Connect with journalists.

Social Media

Education

Featured Articles

2025 FDA approvals

How common is Alzheimer's? Blood-test study holds surprises

FDA approves first gene therapy from a non-profit organization, but pricing and access questions remain

Betting on β-catenin inhibitors in oncology

Novel antimalarial passes key phase III test